Abbott Announces TCT 2009 Activities
"As part of our continued leadership in advancing the treatment of vascular disease and improving patient care, we look forward to the presentations of SPIRIT III and SPIRIT IV data, which promise to provide important insights about the performance and safety of our market-leading XIENCE V drug eluting stent," said Robert Hance, senior vice president, vascular, Abbott. "With our vascular division headquarters and thousands of company employees in the Bay Area, Abbott is looking forward to welcoming the TCT conference and physicians from around the world to San Francisco."
Key presentations and events are as follows (all times are Pacific; all events are at the Moscone Center unless otherwise noted):
Monday, Sept. 21:
Tuesday, Sept. 22:
Wednesday, Sept. 23:
Thursday, Sept. 24:
Throughout the week, Abbott will showcase its latest products at booth #1316 in the exhibit hall. The booth also will feature Abbott's vascular pipeline, as well as resources and programs for physicians and patients, such as Abbott's new Women's Heart Health Initiative.
About XIENCE V
Abbott's market-leading XIENCE V drug eluting stent is marketed in the United States, Europe and other international markets. XIENCE V is an investigational device in Japan and is currently under review by Japan's Ministry of Health, Labour and Welfare and the Pharmaceuticals and Medical Devices Agency.
Everolimus, developed by Novartis Pharma AG, is a proliferation signal inhibitor, or mTOR inhibitor, licensed to Abbott by Novartis for use on its drug eluting stents. Everolimus has been shown to inhibit in-stent neointimal growth in the coronary vessels following stent implantation, due to its anti-proliferative properties.
XIENCE V is indicated for improving coronary luminal diameter in patients with symptomatic heart disease due to de novo native coronary artery lesions (lesions less than or equal to 28 mm) with reference vessel diameters of 2.5 mm to 4.25 mm. Additional information about XIENCE V, including important safety information, is available online at www.xiencev.com or www.abbottvascular.com/en_US/content/document/eIFU_XienceV.pdf.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products.
Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs more than 72,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at www.abbott.com.
-- SPIRIT III: Three-year results from SPIRIT III, a large-scale pivotal clinical trial comparing XIENCE V to TAXUS in 1,002 patients, will be presented by Gregg W. Stone, M.D., of Columbia University Medical Center and principal investigator of the SPIRIT III trial, during the Drug-Eluting Stent (DES) Summit at 5:43 p.m. in Room 104.
You May Also Like